RCT Comparing Avatar Intervention to Supportive Intervention to Reduce

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to conduct a single-blind randomized controlled trial to verify whether the Avatar Intervention has greater efficacy over supportive intervention to reduce cannabis use in patients with psychotic disorders.

Clinical Trial Description

Psychotic disorders (PD) are characterized by a loss of contact with reality. Cannabis use is one of the key factors leading to psychiatric re-hospitalization in PD. In these populations, cannabis use is also associated with depressive symptoms, medication non-compliance, hostility as well as reduced quality of life. Unfortunately, there is no evidence-based intervention available for the treatment of cannabis use disorder (CUD) in this population. Novel interventions for CUD are thus critically needed. Virtual reality-based therapies are a promising avenue that allow patients to try novel strategies in real time instead of having to learn abstract rules. To fill a clinical need, the investigators have created a distinctive intervention for CUD in patients with PD. The Avatar Intervention displays strong experiential and relational components that are crucially missing in conventional interventions. Hence, the primary outcomes are reductions in cannabis use, cannabis use disorder severity, and increased quality of life. The investigators will also explore whether the greater improvements attributable to the Avatar Intervention persist in time, and perform analyses on sex/gender, motivation to change cannabis habits, psychotic relapses, and THC metabolite levels. Noteworthily, cannabis-related hospitalizations have been identified as one of the core indicators to measure the success of cannabis legalization. As a result, there is a pressing need to design innovative interventions that could have a significant impact on this costly and prime outcome. As there is no evidence-based therapeutic options for CUD in patients with PD, the current trial will contribute to the validation of a novel approach and create new therapeutic possibilities. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05704582
Study type	Interventional
Source	Ciusss de L'Est de l'Île de Montréal
Contact	Alexandre Dumais, MD, PhD
Phone	514-251-4000
Email	contact@avatar-intervention.ca
Status	Recruiting
Phase	N/A
Start date	February 1, 2023
Completion date	January 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321602` - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder	Phase 1
Terminated	`NCT03230097` - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year	Phase 2
Completed	`NCT03497663` - VIA Family - Family Based Early Intervention Versus Treatment as Usual	N/A
Active, not recruiting	`NCT05726617` - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders	N/A
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Recruiting	`NCT02874573` - Tocilizumab in Schizophrenia	Phase 1
Completed	`NCT02906553` - The Role of Nitric Oxide in Cognition in Schizophrenia	N/A
Terminated	`NCT02584114` - Brain Effects of Memory Training in Early Psychosis	N/A
Withdrawn	`NCT02213887` - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications	Phase 4
Completed	`NCT01981356` - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis	Phase 0
Terminated	`NCT02841956` - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement	N/A
Recruiting	`NCT02848469` - Irish Omega-3 Study	Phase 2
Recruiting	`NCT02009969` - Serial Comparisons of Abdominal and Neurological MRI Scans	N/A
Completed	`NCT02648321` - Motivational Intervention for Physical Activity in Psychosis	N/A
Enrolling by invitation	`NCT00762866` - Psychiatric Genotype/Phenotype Project Repository
Completed	`NCT00484302` - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis	N/A
Completed	`NCT00844922` - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)	Phase 2
Completed	`NCT00455234` - Rapid Tranquillization Trial: TREC-India II	Phase 3
Completed	`NCT00130923` - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder	Phase 4
Completed	`NCT00226278` - Safety Study of ORG 34517 for Major Depression With Psychotic Features	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders — AC2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms